Vivos Therapeutics (VVOS) Stock Price, News & Analysis $15.31 -0.58 (-3.65%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$15.12▼$16.2150-Day Range$2.73▼$108.0052-Week Range$2.73▼$74.05Volume216,706 shsAverage Volume2.93 million shsMarket Capitalization$20.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesDecember 4, 2023 | marketbeat.comBlack Swan: this small cap surged over 1000% last weekVivos Therapeutics experienced a rare 'black swan' event, surging over 1000% in a single day following breaking news, here's how to look at VVOS stock nowDecember 1, 2023 | proactiveinvestors.comVivos Therapeutics severe sleep apnea treatment’s a ‘breakthrough’, says CEODecember 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 30, 2023 | benzinga.comThinking about buying stock in Minim Inc, Walmart, Farfetch Ltd, Qualcomm, or Vivos Therapeutics Inc?November 30, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Down 35% Today?November 30, 2023 | msn.comPhilips shares slump as FDA says sleep product may overheatNovember 29, 2023 | proactiveinvestors.comVivos Therapeutics: Who is the medical device company creating frenzy in the markets?November 29, 2023 | proactiveinvestors.comVivos Therapeutics receives first ever FDA 510(k) clearance...Vivos Therapeutics receives first ever FDA 510(k) clearance for...December 10, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 29, 2023 | msn.comVivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearanceNovember 29, 2023 | finance.yahoo.comUPDATE 2-US FDA clears Vivos Therapeutics' oral device for sleep apneaNovember 29, 2023 | finance.yahoo.comVivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apneaNovember 29, 2023 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 290% Today?November 29, 2023 | reuters.comUS FDA clears Vivos Therapeutics' oral device treatment for sleep apneaNovember 29, 2023 | markets.businessinsider.comVivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaNovember 29, 2023 | markets.businessinsider.comVivos Receives FDA 510(k) Clearance For Removable Oral Appliances For Severe OSANovember 29, 2023 | msn.comVivos stock rallies after FDA clears oral device treatment for severe sleep apneaNovember 29, 2023 | finance.yahoo.comVivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep ApneaNovember 15, 2023 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational UpdateNovember 14, 2023 | finance.yahoo.comVivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational UpdateNovember 9, 2023 | finance.yahoo.comVivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference CallNovember 3, 2023 | finance.yahoo.comVivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer LincareNovember 3, 2023 | proactiveinvestors.comVivos Therapeutics closes $4M private placementNovember 2, 2023 | finance.yahoo.comVivos Therapeutics Closes $4 Million Private PlacementNovember 1, 2023 | msn.comVivos Therapeutics (VVOS) Price Target Increased by 2400.00% to 45.90October 31, 2023 | msn.comVivos Therapeutics prices $4M public offeringOctober 31, 2023 | finance.yahoo.comVivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,840,000.00 Net Margins-106.28% Pretax Margin-106.27% Return on Equity-508.27% Return on Assets-129.15% Debt Debt-to-Equity RatioN/A Current Ratio0.28 Quick Ratio0.28 Sales & Book Value Annual Sales$16.02 million Price / Sales1.27 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / Book3.19Miscellaneous Outstanding Shares1,330,000Free Float1,204,000Market Cap$20.36 million OptionableNot Optionable Beta8.80 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 65)Co-Founder, Chairman of the Board & CEO Comp: $454.05kMr. Bradford K. Amman (Age 61)CFO, Treasurer & Secretary Comp: $297.23kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder, Executive VP & Chief Experience OfficerMs. Julie GannonSenior VP of Product, Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of DSO OperationsMore ExecutivesKey CompetitorsMinerva SurgicalNASDAQ:UTRSFemasysNASDAQ:FEMYNephrosNASDAQ:NEPHSeaStar MedicalNASDAQ:ICUSTRATA Skin SciencesNASDAQ:SSKNView All CompetitorsInsidersRonald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)Ronald Kirk HuntsmanBought 600 shares on 6/16/2023Total: $8,100.00 ($13.50/share)Ronald Kirk HuntsmanBought 400 shares on 6/14/2023Total: $4,900.00 ($12.25/share)Ronald Kirk HuntsmanBought 800 shares on 12/23/2022Total: $10,000.00 ($12.50/share)View All Insider Transactions VVOS Stock Analysis - Frequently Asked Questions Should I buy or sell Vivos Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vivos Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VVOS shares. View VVOS analyst ratings or view top-rated stocks. How have VVOS shares performed in 2023? Vivos Therapeutics' stock was trading at $10.05 at the beginning of 2023. Since then, VVOS shares have increased by 52.3% and is now trading at $15.31. View the best growth stocks for 2023 here. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) posted its earnings results on Tuesday, November, 14th. The company reported ($1.75) EPS for the quarter. The company had revenue of $3.30 million for the quarter. Vivos Therapeutics had a negative trailing twelve-month return on equity of 508.27% and a negative net margin of 106.28%. When did Vivos Therapeutics' stock split? Vivos Therapeutics shares reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? (VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Vivos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bradford K Amman and Ronald Kirk Huntsman. View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.